|
Ship's medical department is responsible for determining the quality of the water. The ships engineering section determines the quantity stored or produced, and performs the actual chlorination or bromination. Water Testing Naval vessels follow water testing requirements and procedures outlined in the latest edition of Standard Methods for the Examination of Water and Wastewater, published by the American Public Health Association APHA ; , American Water Works Association AWWA ; , and the Water Pollution Control Federation WPCF ; . Manufacture and Handling of Ice Most ships and shore activities use ice machines to make ice. To reduce bacterial growth, ice used around food or in food or drink must be made from potable water. All ice must be prepared in a sanitary manner and afforded the same protection as potable water. The medical departments aboard ships are required to include ice samples in any bacteriological analyses they perform on water. WASTEWATER TREATMENT AND DISPOSAL Wastewater is the spent water of a ship, base, industrial plant, or other activity. This spent water contains wastes, such as soil, detergent, and sewage. The proper disposal of these waste materials is one of the most important measures for controlling water-borne diseases, such as cholera and typhoid fever. Wastewater Treatment and Disposal Systems Ashore The use of approved municipal or regional wastewater collection and disposal systems is the preferred method for disposing of wastes from shore activities. Accordingly, municipal or regional wastewater disposal systems are used by Navy shore activities whenever feasible. Wastewater Treatment and Disposal Systems Afloat The overboard discharge of untreated sewage from DoD ships within the navigable waters of the United.
Route of administration. The doses used were 0.1 and 0.2 mg kg1, and the administration of postoperative opioids did not differ between intervention and control groups, but one42 did not use a standardized anaesthetic technique. The authors investigated the possibility of confounding as a result of this, but were unable to find any significant differences between the groups. The summary OR for the effect of tropisetron on POV was 0.15 95% CI 0.060.35 ; . There was no evidence of heterogeneity between groups I2 0% ; . Figure 6 shows that the effect of tropisetron appears to increase with dose. Dolasetron Only one published trial has tested the efficacy of dolasetron.94 This was a small study using a standardized anaesthetic technique. Dolasetron had a clinically important treatment effect OR 0.25, 95% CI 0.10.59 ; . The use of postoperative opioids was not reported. Pooled estimate for anti-serotinergic agents We performed a pooled estimate of the overall effect of anti-serotinergic agents using the data from the most effective dose of each of the four drugs. The summary OR for anti-serotinergic agents combined was 0.12 95% CI 0.070.20 ; using a fixed effect model. Although.
30 per session. Please indicate preference for each day Monday 17 October 1 [ 2 Professor Pier Luigi Zinzani Treatment of primary mediastinal large B-cell lymphoma ] Dr Ayalew Tefferi Controversial issues in ET PV Alois Gratwohl Autoimmunity in HSCT ] Dr Jill Storry Challenging serological problems ] Dr Roger Dodd Assessing risk Tuesday 18 October 6 [ 7 Professor Lynn Boshkov Does non-leukodepleted blood kill? ] Dr Margaret Goodell Stem cell research: tricks of the trade ] Ms Sandra Gray Ms Liz Pirie Developing the role of the specialist transfusion practitioner ] Dr Thomas Kipps CLL the clinical impact of translational research ] Dr Agnes Lee Challenges in coagulation A.
THE IMPACT OF ELECTRONIC MEDICAL RECORDS ON PHARMACY PRACTICE IN A PEDIATRIC HOSPITAL Stephanie L. Schoenjahn * , Richard T. Smolarek, Cynthia T. Reid, Thomas L. Schaible, Victoria Tutag Lehr Children's Hospital of Michigan-Detroit Medical Center, 3901 Beaubien Blvd., Detroit, MI, 48201 sschoen dmc Background: The electronic medical record EMR ; is a medical record in digital format. This innovative technology facilitates accessible, comprehensive, and continuous patient care. EMR compiles patient specific information relating to medical and non-medical care, assisting health care professionals in providing optimal care and the safest environment possible. Implementation of EMR forces numerous changes in the practice habits for all personnel, but promises advances with enhanced readability, availability, and data quality. Recently, EMR has gained approval as a valuable tool and has become part of recommended standards in many professional organizations and federal agencies. EMR has been proposed as a method to reduce practice variation and improve quality by increasing efficiency of documentation, prompting of clinicians for alerts, decision support, presentation of data, and access to educational materials for patients. Purpose: The present study will determine how implementation of an EMR system impacts pharmacy practice and quality of care in a pediatric hospital. Methodology: This comparative study is designed to assess pre- and postEMR procedures and pharmacy practice information. Pre-EMR data will be obtained from pharmacy records and databases from 2006. Post-EMR data will be collected from the EMR system database and computer medication requests during the first quarter of 2007. An analysis will be performed to determine changes in missing medication requests, medication variances and adverse drug event reports from the hospital quality database, and order entry to delivery times. Data analysis will be performed using a student's t-test. This study has been approved by the Institutional Review Board. Results Conclusions: Data collection is in progress. Results will be used to address the benefits and limitations of use with the new EMR system. Conclusions will be presented at the Great Lakes Pharmacy Resident conference. Learning Objectives: Define electronic medical record. Identify two benefits of an electronic medical record versus a paper chart system. Self Assessment Questions: Electronic medical records facilitate patient care because they are: A. Accessible B. Comprehensive C. Continuous D. All of the above Electronic medical records have become part of recommended standards in many professional organizations and federal agencies. T or F.
WHAT ARE THE CONTRA-INDICATIONS TO THE USE OF BETA2 STIMULANTS IN SUPPRESSING LABOUR? Heart valve disease. The use of beta2 stimulants, such as hexoprenaline, can endanger the patient's life, especially if she has a narrowed heart valve, e.g. mitral stenosis. A shocked patient. A patient with a tachycardia, e.g. as the result of an acute infection. HOW SHOULD YOU USE HEXOPRENALINE FOR THE SUPPRESSION OF PRETERM LABOUR? Two ampoules 2 x 2 ml 10 mg ; of hexoprenaline Ipradol ; are administered slowly 0, 5 ml per minute ; intravenously while the maternal heart rate is carefully monitored for a tachycardia. Six ampoules 30 mg ; hexoprenaline Ipradol ; in 200 ml saline are then administered as a side infusion. The speed of administration is determined by the mother's pulse rate. Start at 10 drops per minute and increase by 5 drops every 10 minutes, until the contractions have stopped or the maternal pulse rate reaches 120 beats per minute. The administration of the hexoprenaline infusion is continued until there have been no further contractions, or effacement and or dilatation of the cervix for at least 6 hours. The patient must be warned that hexoprenaline causes tachycardia palpitations.
Table 1. Distribution of amphotericin B and flucytosine MICs and MFCs against C. inconspicua MIC and MFC mg L ; distributions Test method Amphotericin B BMDa Etest 24 h Etest 48 h MFC BMDa MFC 0.06 0 1 0 0.12 0 23 1 0.25 MIC50 90 1 and nimotop!
Plate. Shorter reaction products point to enzyme pausing in the absence of INDOPY-1. In the presence of the inhibitor, additional, distinct bands appear following incorporation of pyrimidines mainly thymidine ; . The next base in the template, ahead of the 3 end of the primer, which determines the specificity of binding and incorporation of NRTIs through base pairing, does not appear to influence the inhibitory effects of.
Table of Contents We are aware of several companies focusing on the development of active immunotherapies for NHL, including Genitope Corporation, Antigenics, Inc., Favrille, Inc., and Large Scale Biology Corporation. We believe none of these companies uses the hybridoma method to produce a patient-specific vaccine, and of these companies, only Genitope and Favrille have a product candidate in Phase 3 clinical trials. Several companies, such as Genentech, Inc., Curia Corporation, Biogen Idec, and Immunomedics, Inc., are involved in the development of passive immunotherapies for NHL. These passive immunotherapies include Rituxan, a monoclonal antibody, and Zevalin and Bexxar, which are passive radioimmunotherapy products. Competition could impair our ability to generate revenue and could increase costs. Our proprietary rights may not adequately protect our technologies and product candidates. Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our technologies and product candidates as well as successfully defending these patents against third-party challenges. We will only be able to protect our technologies and product candidates from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover them. Furthermore, the degree of future protection of our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. In addition to the patent applications that we have filed and the patent we hold relating to the method of producing BiovaxID, SinuNase is the subject of a patent that we license from MAYO that expires in 2018. The MD Turbo device is the subject of four issued U.S. patents and one pending U.S. application that are held by Respirics, Inc., our development partner for MD Turbo, and these patents expire in 2016. The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies' patents has emerged to date in the United States. The patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States or other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. For example: we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents; we or our licensors might not have been the first to file patent applications for these inventions; others may independently develop similar or alternative technologies or duplicate any of our technologies; it is possible that none of our pending patent applications or the pending patent applications of our licensors will result in issued patents; our issued patents and issued patents of our licensors may not provide a basis for commercially viable products, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; we may not develop additional proprietary technologies or product candidates that are patentable; or the patents of others may have an adverse effect on our business and relafen.
Dear Readers of The Bonaire Reporter, It was quite a while ago that we, for the last time, read about the wonderful 98 % on time flight results of Air Exel. Why? Because they do not fly on time any more. My recent experiences have been very disappointing. At the end of May a direct flight to Aruba had a two hour delay. In addition, without notifying the passengers, the flight had a nonscheduled stop in Curaao which costs you another hour. A couple of weeks ago I checked in for Curaao. When receiving the boarding card I was advised the boarding time was one hour later than planned. When I asked why they did not give me a call, the answer simply was: "It is only a delay of one hour, we call our clients when the delay is more than one and a half hours." Due to the delay I had time to find out why I was stuck at the airport. The answer was the same answer I received in May: "We only have one plane available, so we have to delay and reschedule flights all the time." Would it be an idea NOT to sell tickets for non-existing flights? I never had these experiences with Exel in The Netherlands. What is it with Caribbean based airlines?! Yvonne Nuijts Dear Readers, Customers and Others interested in BonairExel: BonairExel is rapidly approaching its first birthday and we are very proud of what we have achieved in the last 12 months. But we leave the `back patting' to others, while our focus remains on continuous improvement of our services and network. The letter of Mrs. Nuijts proves clearly that there is still room for improvement. BonairExel has faced quite some challenges in the last months. For a period of time, we have hardly been able to keep our schedules, as a result of technical and operational problems. Throughout these challenges, our aim has always been to minimize passenger inconvenience. We truly believe that making the difference comes from solutions offered and not from problems experienced. Contacting passengers that will be delayed is one of these `solutions' and we can proudly say that most passengers highly appreciate this service. Combining flights to make sure that all passengers will reach their final destination is another solution, which might create inconvenience for some but will benefit many more. The fact that we had the challenges as described above is not surprising. Every start-up company will eventually face some setbacks during its initial months. We have had our share, from which we learned. Along the road, we have made adjustments in the way we communicate with our valuable customers and we will continue to do so. For all customers who have lost faith in BonairExel over the last months, we offer our sincerest apologies. Being part of a small community as Bonaire, we are very much aware of our image on the island and on the sister islands. It is this image and our desire to stand out in a positive way that keeps us going in what we believe is the right direction. There is a lot to gain, still, and the airline group will not stop short of its goal to become a leading airline in the region. Arian van der Werff, BonairExel Deputy General Manager.
Accuretic Accutane Achromycin Actigall Adalat CC Adderall Adipex-P Aldactazide Aldactone Aldoril Alphagan Alupent Amikin Amoxil Anafranil Anaprox Ansaid Antivert Apresoline Aristocort * Aristocort A * Artane Atarax Ativan Atromid-S Atrovent Augmentin Aventyl * Axid Azulfidine Bactocill Bactrim Bancap HC * Benadryl Bentyl * Betagan Betapace Blocadren Brethine Bumex Brand Medically Necessary Drugs That Require Prior Authorization Buspar Depakene Fulvicin U F * Butisol Sodium Elixir Desyrel Furacin Calan Dexedrine Garamycin * Calciferol Diabinese Glucophage Capoten Diamox Glucotrol Capozide Dilacor XR * Glucovance Carafate * Dilantin Kapseal Glynase Prestab Cardene Diprolene * Halcion Cardizem * Diprosone * Haldol Cardura Ditropan Haldol Decanoate Cataflam Diuril Hydrea Catapres Dolobid Hydrodiuril Ceclor Doryx * Hytone * Ceftin * Duricef * Hytrin Chloromycetin Dyazide Imdur * Chloroptic EC-Naprosyn Imuran Cleocin E.E.S. Inderal Cleocin T Elavil Inderide Clinoril Elixophyllin * Indocin * Clozaril Elocon * Inflamase Forte Cogentin Enduron Inflamase Mild Compazine Eryc * Intal Nebulizer Solution * Copegus Erycette Isoptin Cordarone Erygel * Isordil Corgard Eryped K-Dur * Cortef Ery-tab Keflex Cortisporin Esgic-Plus * Kenalog Coumadin Eskalith Kenalog with Orabase Cutivate Estrace * Kerlone * Cyclogyl Eulexin * Klonopin Cylert Eldene Lac Hydrin Cytotec Fioricet Lanoxin Dalmane Fiorinal Lasix * Danocrine * Flagyl Lidex * Darvocet N 100 Flexeril Limbitrol Daypro Florinef Lioresal DDAVP * Floxin Lodine Decadron Flumadine * Lomotil Deltasone Fml Loniten Demadex Fulvicin P G * Luvox and motrin.
Congratulations to the following residents who completed their pediatric training at greenville hospital system children's hospital this spring.
The overall pattern of changes in the physiologic variables measured in the 16 patients at baseline and after ACZ administration was similar to that of the healthy volunteers studied for our previous report. Of the 6 physiologic parameters, tO2c 0.167 0.020 [at baseline] and 0.173 0.020 [after ACZ] ; and PaO2 76.7 10.97 mm Hg [at baseline] and 90.2 11.7 mm Hg [after ACZ] ; were significantly different between the baseline and ACZ-challenge conditions P 0.001 ; . Mean blood pressure and PaCO2, which may affect the CBF values, did not change during the study. Figure 1 shows the changes in rCBF and V0 in the cortical territories of the right and left MCAs at baseline and after ACZ administration. Four of the 16 patients showed a reduction in rCBF in the ipsilateral hemisphere of the occlusive artery after the ACZ injection, although the V0 in all 4 patients increased on the same side. The hemispheres contralateral to the arterial occlusion showed regional values and changes in both rCBF and V0 similar to those in healthy volunteers. The mean regional values for each hemisphere in the patients and in the 16 hemispheres of the 8 healthy volunteers are given in Table 2. Both hemispheres in the patients showed a significant increase in rCBF and V0, although the percentage change in rCBF was significantly smaller in the ipsilateral hemisphere than in the contralateral hemisphere P 0.005 ; or in healthy volunteers P 0.001 ; . The rCBF and V0 in patients were significantly different between the 2 hemispheres for both conditions and aleve.
Table 1. Comparison of Transplant and Nontransplant Cohorts.
It is also used alone or in combination with peginterferon to treat hepatitis pirox piroxicam , feldene ; used to relieve the pain, tenderness, inflammation swelling ; , and stiffness caused by arthritis and azulfidine.
Pathological changes in the gastrointestinal tract in patients with scleroderma can result in reduced colonic motility and prolonged transit time, which may lead to a state of chronic colonic pseudo-obstruction. In case reports, four patients with scleroderma developed severe abdominal pain after initiation of a high-fiber diet for the treatment of constipation; three of these patients required hospitalization.1 The authors of this report suggested that, for patients with scleroderma, any increase in dietary fiber intake should be undertaken cautiously and introduced gradually.
Adams JM and Cory S 1998 ; The Bcl-2 protein family: Arbiters of cell survival. Science Wash DC ; 281: 13221326. Anversa P, Olivetti G, Leri A, Liu Y and Kajstura J 1997 ; Myocyte cell death and ventricular remodeling. Curr Opin Nephrol Hypertens 6: 169 176. Ashkenazi A and Dixit VM 1998 ; Death receptors: Signaling and modulation. Science Wash DC ; 281: 13051308. Bromme HJ and Holtz J 1996 ; Apoptosis in the heart: When and why? Mol Cell Biochem 163: 261275. Cascales M, Alvarez A, Gasco P, Fernandez-Simon L, Sanz N and Bosca L 1994 ; Cocaine-induced liver injury in mice elicits specific changes in DNA ploidy and induces programmed death of hepatocytes. Hepatology 20: 9921001. Casciola-Rosen L, Rosen A, Petkm M and Schlissel M 1996 ; Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implication for coagu and mobic.
2. articles have been published in leading scientific journals. Accordingly, I requesting by my client to request that the university provide complete details as to the results of the probe of inquiry undertaken and the conclusions arising therefrom. My client has requested and thofany and all documentation relating to the findings~. undertaken .requestedaacopy ofconclusions arising therefrom. My client - findings copy anyand all documentation relating to the has of such a probe of inquiry. My client has indicated that if he does not receive complete details with respect of the subject probe forthwith, he will conclude that the university never had a bonafide intention of fairly dealing with the nature of his complaints. In this regard, my client is of the opinion that the failure of university officials to properly deal with the subject matter of his complaint is an indication that the university lacks a bonafide interest in supporting basic scientific research. Unless I in receipt of the information requested herein within 7 days of the date of this letter, my client has indicated an intention to forthwith pursue his complaints in both the public and political forums. I await your response. Yours very truly, DAVIS & ASSOCIATES.
1. 2. 3. Thurlimann B, de Stoutz ND. Causes and treatment of bone pain of malignant origin. Drugs 1996; 51: 383-398. Payne R. Mechanisms and management of bone pain. Cancer 1997; 80 suppl ; : 1608-1613. Bushnell TG, Justins DM. Choosing the right analgesic. A guide to selection. Drugs 1993; 46: 394-408. Gordon RL. Prolonged central intravenous ketorolac continuous infusion in a cancer patient with intractable bone pain. Ann Pharmacother 1998; 32: 193-196. Levick S, Jacobs C, Loukas DF, et al. Naproxen sodium in treatment of bone pain due to metastatic cancer. Pain 1988; 35: 253-258. Lomen PL, Samal BA, Lamborn KR, et al. Flurbiprofen for the treatment of bone pain in patients with metastatic breast cancer. J Med 1986; 80: 83-87. Gotzsche P. Non-steroidal anti-inflammatory drugs. BMJ 2000; 320: 1058-1061. Bailes J. Cost aspects of palliative cancer care. Semin Oncol 1995; 22 suppl 3 ; : 64-66. [No author listed.] Drug Facts and Comparisons. St. Louis, MO: Facts and Comparisons; 2000. Moore RA, Tramer MR, Carroll D, et al. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998; 316: 333-338. Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions. A review of the literature. Drugs 1998; 56: 783-799. El-Faham TH, Safwat SM. Comparative study of the release and anti-inflammatory activity of indomethacin from topical formulations. Pharm Ind 1992; 54: 82-86. Indocin [package insert].West Point, PA: Merck; 1998. Felden [package insert]. Memphis, TN: Pfizer; 1999 and indocin.
PRECAUTIONS General FELDENE cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. The pharmacological activity of FELDENE in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions. Hepatic Effects Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including FELDENE. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST approximately three or more times the upper limit of normal ; have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported. A patient with symptoms and or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of more severe hepatic reaction while on therapy with FELDENE. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur e.g., eosinophilia, rash, etc. ; , FELDENE should be discontinued see ADVERSE REACTIONS ; . Hematological Effects Anemia is sometimes seen in patients receiving NSAIDs, including FELDENE. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including FELDENE, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia. NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving FELDENE who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored. Ophthalmologic Effects Because of reports of adverse eye findings with nonsteroidal anti-inflammatory agents, it is recommended that patients who develop visual complaints during treatment with FELDENE have ophthalmic evaluations. Preexisting Asthma Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm which can be fatal. Since crossreactivity, including bronchospasm, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, FELDENE should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.
Ventricular repolarization, as reflected in the surface QT interval, can be affected by drugs as well as autonomic state, both directly and via their effects on heart rate HR ; . Methods to normalize the QT interval for changes in heart rate have been described since early last century Bazett, 1920; Fridericia, 1920 ; . Bazett noted in his original proposal that the K from his correction factor of K RR varied when the vagus nerve was sectioned or stimulated. Simonsen et al. 1962 ; demonstrated discrepancies in eight different correction factors when modeling the HR-QT interval relationship on the same dataset. Browne et al. 1982 ; later showed that a 75-ms shortening of the absolute QT interval with atropine and colchicine.
NDA 18-147 S-029 Page 18 Generic Name Etodolac Fenoprofen Flurbirofen Ibuprofen Tradename Lodine, Lodine XL Nalfon, Nalfon 200 Ansaid Motrin, Tab-Profen, Vicoprofen combined with hydrocodone ; , Combunox combined with oxycodone ; Indomethacin Indocin, Indocin SR, Indo-Lemmon, Indomethagan Ketoprofen Oruvail Ketorolac Toradol Mefenamic Acid Ponstel Meloxicam Mobic Nabumetone Relafen Naproxen Naprosyn, Anaprox, Anaprox DS, EC-Naproxyn, Naprelan, Naprapac copackaged with lansoprazole ; Oxaprozin Daypro Piroxicam Eldene Sulindac Clinoril Tolmetin Tolectin, Tolectin DS, Tolectin 600 This Medication Guide has been approved by the U.S. Food and Drug Administration.
A Accutane * Adalat CC * Adderall * Adderall XR Is Tier 3 ; Aldactazide * Aldactone * Aldomet * Alupent * Ambenyl * Amoxil * Anaprox * Android * Ansaid * Antabuse * Antivert * Anturane * Anusol-HC * Apresazide * Apresoline * Apri * Aquasol A * Artane * Atarax * Ativan * Atrovent Inh., Sol * Augmentin * Augmentin ES, XR are Tier 3 ; Auralgan Otic * Aviane * Axid * Azulfidine * B Bactrim * Bactrim DS * Bellergal-S * Benemid * Bentyl * Benzamycin Gel * Betagan * Betapace * Betoptic Betoptic S Bleph 10 * Blephamide * Bumex * Buspar * C Calan SR * Calan * Camila * Capoten * Carafate * Cardizem CD * Cardizem SR * Cardizem * Cardura * Catapres * Ceclor * Ceftin tablets only * Chronulac * Cleocin T gel * Cleocin T * Cleocin * Clinoril * Cloxapen * Clozaril * Codimal LA * Cogentin * Col-Benemid * Combipres * Compazine * Cordarone * Corgard * Cortef * Cortenema * Cortisporin * Cortone * Cryselle * Cylert * Cytoxan * D Dalmane * Darvocet-N * Daypro * DDAVP Tablets * Decadron * Demerol * Depakene * Depo-Estradiol * Desowen * Desyrel * Diabinese * Diamox * Diflucan * NEW! ; Diprosone * Disalcid * Ditropan * Dolobid * DuraVent DA * Duricef * Dyazide * Dymelor * Dynapen * E E.E.S. * Elavil * Eldepryl * Elimite * Elixophyllin * Empirin #3 * Enpresse * Eryc * Erygel * Eryped * Erythrocin Stearate * Eskalith * Estrace * F Felene * Fioricet * Fioricet #3 * Fiorinal * Fiorinal #3 * Flagyl * Flagyl 375mg and 750mg are Tier 3 ; Flexeril * Florinef * Fml * Folvite * Fulvicin P G * G Gantrisin * Garamycin * Glucophage * Glucotrol * Glynase PresTab * Golytely * H Halcion * Haldol * Haldol Conc * Histinex D * Humabid DM * Humabid LA * Hydrea * Hydrodiuril * Hygroton * Hytone * Hytrin * I Ilosone * Ilotycin Ophth. * Imdur * Imuran * Inderal * Inderide * Indocin * Indocin SR * Intal * Isopto Homatropine * Isordil * Isordil Tembids * K Kayexalate * Keflex * Kenalog * Kenalog in Orabase * Klonopin * Kwell * L Lac-Hydrin * Lasix * Lessina * Levbid * Levora * Levsin * Levsin SL * Librax * Librium * Lidex E * Lidex * Lioresal * Loestrin Fe * Lomotil * Lopid * Lopressor * Lorcet Plus * Lortab * otrisone Cream * Lo-Ogestrel and vibramycin and Feldene online.
ACTH independent. However, the process to reach that end point still remains the issue of debate. The suppressed, atrophic nonnodular cortex provides the link between the biochemical data and the revealing histologic features of AIMAH. As a direct consequence of the autonomous cortisol secretion by the macronodules, the internodular cortex is atrophic. Even beyond this, however, the histologic characteristics and cellular ultrastructure have been carefully studied5 and appear unique. The adrenal glands are composed of an increased number of small clear cells in cordlike arrangements often accompanied by nest-forming compact cells. The great majority of these cells show weak to negligible enzymatic activity and poorly developed smooth endoplasmic reticulum. The purification and characterization of steroidogenic enzymes such as cytochrome P450 have led to the production of antibodies to these enzymes as well as to probes to the encoding messenger RNAs. Studies in patients with AIMAH have demonstrated that cytochrome P450c17 is not produced in the majority of clear cortical cells, and the compact cortical cells do not synthesize 3 -hydroxysteroid dehydrogenase--a pattern unique to AIMAH that has not been observed in other adrenocortical lesions associated with Cushing syndrome.6, 8 This unique localization of steroidogenic.
Cer rates.3. 52 Carcinoma of the pan creas and bladder is also more common in cigarette smokers than in non smokers.3'53 and depo-medrol.
ANTIBIOTICS GENERIC WILL BE DISPENSED Amoxicillin Ampicillin Bactrim Dynapen Erythromycin Keflex Pediazole Penicillin VK Tetracycline Vibramycin BRAND NAME WILL BE DISPENSED Augmentin Cefzil Cipro Zithromax ANTIDEPRESSANTS GENERIC WILL BE DISPENSED Elavil Desyrel Norpramin Pamelor BRAND NAME WILL BE DISPENSED Celexa Effexor Nardil Parnate Paxil Serzone ANTI-VIRAL GENERIC WILL BE DISPENSED Symmetrel Zovirax BRAND NAME WILL BE DISPENSED Combivir Crixivan Epivir Fortovase Hivid Invirase Norvir Rescriptor Retrovir Trizivir Videx Viracept Viramune Zerit ARTHRITIS AND PAIN MEDICATIONS GENERIC WILL BE DISPENSED Clinoril Disalcid Teldene Indocin Lodine Motrin Naprosyn Orudis Tolectin Trilisate Voltaren ASTHMA MEDICATIONS GENERIC WILL BE DISPENSED Metaprel Proventil, Ventolin BRAND NAME WILL BE DISPENSED Accolate Atrovent Maxair Serevent Vanceril, Beclovent CHOLESTEROL LOWERING MEDICATIONS GENERIC WILL BE DISPENSED Lopid Questran BRAND NAME WILL BE DISPENSED Baycol Niaspan Pravachol COUGH, COLD OR ALLERGY MEDICATIONS GENERIC WILL BE DISPENSED Atarax, Vistaril Entex LA Naldecon Phenergan Robitussin AC Rynatan Tavist Zephrex LA BRAND NAME WILL BE DISPENSED Allegra Claritin Flonase Polyhistine Rhinocort Vancenase, Beconase DIABETIC MEDICATIONS GENERIC WILL BE DISPENSED Diabinese Diabeta, Micronase Orinase Tolinase BRAND NAME WILL BE DISPENSED Glucophage Novolin, Humulin ESTROGEN REPLACEMENT MEDICATIONS GENERIC WILL BE DISPENSED Estrace Ortho-Est, Ogen BRAND NAME WILL BE DISPENSED Menest Premarin Premphase, Prempro Estraderm Vivelle HEART BLOOD PRESSURE MEDICATIONS GENERIC WILL BE DISPENSED Aldomet Apresoline Calan, Isoptin Calan SR, Isoptin SR Cardizem Capoten Catapres Dilacor XR Hydrochlorothiazide Hytrin Inderal Lopressor Minipress Normodyne, Trandate Tenormin BRAND NAME WILL BE DISPENSED Adalat CC Cardura DynaCirc Lotensin Nitro-Dur Plendil Sular Tiazac Univasc Zestril MEDICATIONS FOR STOMACH AILMENTS GENERIC WILL BE DISPENSED Carafate Reglan Tagamet Zantac BRAND NAME WILL BE DISPENSED AcipHex 8 Wks. ; Protonix 8 Wks. ; MUSCLE RELAXANTS GENERIC WILL BE DISPENSED Flexeril Norflex Robaxin ORAL CONTRACEPTIVES BRAND NAME WILL BE DISPENSED Alesse Brevicon Demulen Desogen Jenest Lo Ovral Mircette Nordette Norinyl Nor QD Ovral Tri-Norinyl Triphasil THYROID REPLACEMENTS BRAND NAME WILL BE DISPENSED Levoxyl Levothroid TRANQUILIZERS OR SLEEPING MEDICATIONS GENERIC WILL BE DISPENSED Ativan Dalmane Halcion Librium Restoril Serax Valium Xanax.
Retinol-binding protein 4 RBP-4 ; levels do not change after oral glucose tolerance test in obese and overweight individuals, but correlate with some indices of insulin resistance K. C. Lewandowski, M. Basinska-Lewandowska, M. Bienkiewicz, H. S. Randeva, A. Lewinski Poland, United Kingdom!
ANTI-INFECTIVE AGENTS ORAL ; ANTIBIOTICS Cephalosporins Cefaclor generic Ceclor ; Cefadroxil generic Duricef ; Cephalexin generic Keflex ; Erythromycins & Other Macrolides Azithromycin generic Zithromax Z-PAK ; * Clarithromycin generic Biaxin, Biaxin XL ; * Erythromycin Base generic Ery-Tab, EMycin ; Erythromycin Ethylsuccinate generic E.E.S., EryPed ; Erythromycin Stearate generic Erythrocin ; Erythromycin and Sulfisoxazole generic Pediazole ; Penicillins Amoxicillin generic Amoxil ; Amoxicillin Pot. Clav. generic Augmentin ; * Ampicillin generic Principen ; Dicloxacillin generic ; Penicillin VK generic Pen-Vee K ; Quinolones Ciprofloxacin generic Cipro ; * Ofloxacin generic Floxin ; * Sulfonamides TMP-SMX generic Septra Septra DS ; Tetracyclines Doxycycline generic Vibramycin ; Minocycline generic Minocin ; Tetracycline generic Achromycin V ; ANTIFUNGAL AGENTS Clotrimazole generic Mycelex-7 ; Clotrimazole Betamethasone generic Lotrisone ; Econazole generic Spectazole ; Fluconazole generic Diflucan ; * Griseofulvin generic Gris-PEG Grifulvin ; Ketoconazole generic Nizoral ; Metronidazole generic Flagyl ; Nystatin Oral generic Mycostatin ; Tolnaftate generic ; ANTIFUNGAL VAGINAL ; Clotrimazole generic Myceles ; Fluconazole generic Diflucan ; Miconazole generic Monistat ; ANTIHELMINICS Mebendazole generic Vermox ; ANTI-INFECTIVE AGENTSSPECIALIZED INDICATIONS Chloroquine phosphate generic Aralen ; Ethambutol HCL generic Myambutol ; Hydroxychloroquine generic Plaquenil ; * Mebendazole generic Vermox ; Neomycin generic ; ANTINEOPLASTIC IMMUNOSUPPRESANTS Azathioprine Generic Imuran ; * Cyclophosphamide generic Cytoxan ; Flutamide generic Eulexin ; Hydroxyurea generic Hydrea ; Leucovorin generic Wellcovorin ; Megestrol generic Megace ; Methotrexate generic ; Tamoxifen generic Nolvadex ; ANTI-TUBERCULAR AGENT Ethambutol generic Myambutol ; ANTIVIRAL AGENTS Acyclovir generic Zovirax ; Amantadine generic Symmetrel ; Rimantadine generic Flumadine ; OTHER ANTI-INFECTIVES Clindamycin HCL generic Cleocin ; * Isoniazid generic Nydrazid ; Methenamine generic Urex ; Methanamine Sod Bis Phenyl Salicyl Methylene Blue Hyos generic Urimax ; Nitrofurantoin generic Macrodantin Macrobid ; Rifampin generic Rifadin ; Trimethoprim generic Trimpex ; TOPICAL ANTIBACTERIAL DRUGS Silver Sulfadiazine generic Silvadene ; TOPICAL ANTIFUNGAL AGENTS Ciclopirox generic Loprox ; * Nystatin Triamcinolone generic Mycolog ; AUTONOMIC AND CENTRAL NERVOUS SYSTEM AGENTS ANALGESICS, ANTIMIGRAINAL Pentazocine Naloxone generic Talacen Talwin NX ; Tramadol generic Ultram ; ANALGESICS, NARCOTIC APAP Codeine generic Tylenol w Codeine ; APAP Hydrocodone generic Vicodin Norco ; ASA Codeine generic Empirin w Codeine ; Butalbital Acetaminophen generic Phrenlin, generic Sedapap ; Butabital Acetaminophen Caffeine generic Fioricet ; * Hydrocodone Aspirin generic Lortab ASA ; Hydrocodone Ibuprofen generic Vicoprofen ; Meperidine generic Demerol ; Mepiridine Promethazine generic Mepergan ; Oxycodone generic OxyIR ; Oxycodone APAP generic Percocet ; Oxycodone ASA generic Percodan ; Propoxyphene HCL generic Darvon ; Propoxyphene HCL ASA Caffeine Darvon Compound ; Propoxyphene Napsylate APAP generic Darvocet N-100 Wygesic ; ANALGESICS, NON-STEROIDAL ANTI-INFLAMMATORY Diflunisal generic Dolobid ; Ibuprofen generic Motrin ; Ketorolac generic Toradol ; Meloxicam generic Mobic ; * Naproxen generic Naprosyn ; * Oxaprozin generic Daypro ; Piroxicam generic Feldene ; ANTICONVULSANTS Carbamazepine generic Tegretol ; Clorazepate generic Tranxene ; Divalproex Na generic Depakote Sprinkle, generic Depakote ER ; Ethosuximide generic Zarontin ; Gabapentin generic Neurontin ; * Lithium Carbonate generic ; Phenobarbital generic ; Phenytoin Phenytoin Extended generic Dilantin ; Primdone generic Mysoline ; Valproic Acid Valproate Sodium generic Depakene Depakote ; ANTIPARKINSON AGENTS Amantadine generic Symmetrel ; Benzatropine Mesylate generic Cogentin ; Bromocriptine generic Parlodel ; Carbidopa Levodopa generic Sinemet Sinemet CR ; * Selegiline generic Eldepryl ; Trihexyphenidyl generic Artane ; ANTIPSYCHOTICS Chlorpromazine generic Thorazine ; Clozapine generic Clozaril ; Fluphenazine generic Prolixin ; Haloperidol generic Haldol ; Loxapine generic Loxitane ; Perphenazine generic ; Thioridazine generic Mellaril ; Thiothixene generic Navane ; Trifluoperazine generic Stelazine ; ANTIVERTIGO ANTIEMETICS Hydroxyzine generic Atarax ; Meclizine HCL generic Antivert ; Ondasetron generic Zofran ; * Prochlorperazine generic Compazine ; Promethazine HCL generic Phenergan ; Promethazine HCL Suppository, Rectal generic Phenergan ; Trimethobenzamide generic Tigan ; ANXIOLYTICS, SEDATIVES AND HYPNOTICS Alprazolam generic Xanax ; Aquachloral Supprettes generic Noctec ; Buspirone generic BuSpar ; Chlordiazepoxide HCL generic Librium ; Clonazepam generic Klonopin ; Diazepam generic Valium ; Estazolam generic Prosom ; Flurazepam generic Damane ; Lorazepam generic Ativan ; Oxazepam generic Serax ; Temazepam generic Restoril ; Triazolam generic Halcion ; Zolpidem Tartrate generic Ambien ; * CNS STIMULANTS DRUGS TO TREAT ATTENTION DEFICIT DISORDER Amphetamine Dextroamphetamine generic Adderall ; Dextroamphetamine generic Dexedrine Dextrostat ; Methylphenidate generic Ritalin Methylin ; DRUGS TO PREVENT AND TREAT GOUT Allupurinol generic Zyloprim ; Colchicine generic ; Probenecid generic ; MUSCLE RELAXANTS ANTISPASMODICS Baclofen generic Lioresal ; Carisoprodol generic Soma ; Carisoprodol and Aspirin generic Soma Compound ; Carisoprodol, Aspirin, Caffeine generic Soma Compound with Codeine ; Chlorzoxazone generic Parafon Forte DSC ; Cyclobenzaprine HCL generic Flexeril ; Metaxalone generic Skelaxin ; Methocarbamol generic Robaxin ; Tizanidine generic Zanaflex ; PSYCHOTHERAPEUTIC AGENTS Antidepressants Amitriptyline generic Elavil ; Amitriptyline Chlordiazepoxide generic Limbitrol ; Amitriptyline Perphenazine generic Triavil ; Amoxapine generic Asendin ; Bupropion generic Wellbutrin & Wellbutrin SR, Wellbutrin XL ; Citalopram generic Celexa ; Clomipramine generic Anafril ; Desipramine generic Norpramin ; Doxepin generic Sinequan ; Fluoxetine generic Prozac ; Fluvoxamine generic Luvox ; Imipramine generic Tofranil ; Maprotiline generic Ludiomil ; Mirtazapine generic Remeron ; Nortiptyline generic Pamelor ; Paroxetine generic Paxil ; Sertraline generic Zoloft ; Trazadone generic Desyrel ; CARDIOVASCULAR MEDICATIONS ACE INHIBITORS Captopril generic Capoten ; Enalapril generiv Vasotec ; Lisinopril generic Zestril ; Quinapril generic Accupril ; * ALPHA BLOCKERS Doxazosin generic Cardura ; Prazosin generic Minipress ; Terazosin generic Hytrin ; ANTIARRHYTHMICS Amiodarone generic Cordarone ; Disopyramide generic Norpace ; Mexiletine generic Mexitil ; Nitroglycerin generic ; Procainamide generic Procainamide ; Propafenone generic Rythmol ; Quinidine generic ; BETA-ADRENERGIC ANTAGONISTS Acebutolol generic Sectral ; Atenolol generic Tenormin ; Betaxolol generic Kerlone ; Bisoprolol generic Zebeta ; Carvedilol generic Coreg ; * Labetolol generic Normodyne ; Metoprolol generic Propranolol ; Nadolol generic Corgard ; Pindolol generic Visken ; Propranolol generic Inderal ; Sotalol generic Betapace ; Timolol generic Blocadren ; CALCIUM CHANNEL BLOCKERS Amlodipine generic Norvasc ; * Diltiazem generic Cardizem SR Dilacor XR ; Nicardipine generic Cardene ; Nifedipine generic Procardia XL ; Verapamil generic Calan SR Isoptin SR ; CARDIAC GLYCOSIDES Digoxin generic Lanoxin ; CHOLESTEROL-LOWERING AGENTS Cholestyramine generic Questran Light ; Gemfibrozil generic Lopid ; Lovastatin generic Mevacor ; Niacin generic Niapspan ; Pravastatin generic Pravachol ; * Simvastatin generic Zocor ; * DIURETICS Amiloride HCTZ generic Moduretic ; Bumetanide generic Bumex ; Chlorthalidone generic Hygroton ; Furosemide generic Lasix ; Hydrochlorothiazide generic ; Indapamide generic Lozol ; Methazolamide generic ; Metolazone generic Zaroxolyn ; * Spironolactone generic Aldactone ; Torsemide generic Demadex ; DIURETIC COMBINATIONS Atenolol Chlorthalidone generic Tenoretic ; Bisoprolol Hydrochlorthiazide generic Ziac ; Captopril Hydrochlorthiazide generic Capozide ; Chlorothiazide generic Diuril ; Enalapril Hydrochlorthiazide generic Vasoretic ; Lisinopril Hydrochlorothiazide generic Zestoretic ; Methyldopa Hydrochlorothiazide generic Aldoril.
Immune Support #53560 #53820 #55640 #55490 #54130 #73900 #73500 #55650 #52840 #52080 #51950 #52530 #75600 #55620 #55300 #55670 #55710 #50510 Complete Immune 300 g Complete Immune 900 g CysteinePePTM, caps New . CysteinePePTM, pwd New ImmuBlast . ImmunoPro New . IMUPlus . KingChlorellaTM New . Laktoferrin 90 caps ; . Laktoferrin 120 caps ; . Laktoferrin with Colostrum . Mycocyclin . RenewProTM New . Russian Choice GITM New, see Gastric Nutritional . 7, 36 Russian Choice ImmuneTM, 60 vegicaps New . Russian Choice ImmuneTM, 200 vegicaps New . Russian Choice ImmuneTM, pwd New . Super Immuno Complex, packs 46.
Feldene and piroxicam
The Company is exposed to financial risk arising from fluctuations in foreign exchange rates and the degree of volatility of those rates. The Company does not use derivative instruments to reduce its exposure to foreign currency risk. As at September 30, 2007, the Company had financial assets totalling 4, 489, 729 3, 872, 919 in 2006 ; including cash and buy nimotop.
Rvita: arthritis and willow bark overview national center for complementary and alternative medicine: rheumatoid arthritis and complementary and alternative medicine healthworld online: cayenne -this popular herb is hot wisdom, blogs and message boards about piroxicam revolution health: piroxicam feldene ; reviews dailystrength: does anyone take this.
Buy Feldene online
Been proven. In fact, limited evidence suggests that low bone mineral density, as identified by dualenergy x-ray absorptiometry DEXA ; , is not a risk factor for future fracture.124, 125 There is no doubt, however, that pathological fractures are common after renal transplantation. The estimated total fracture rate after renal transplantation, which is 2% per year in nondiabetic patients, 5% per year in type 1 diabetic patients, and up to 12% per year in pancreas-kidney recipients.126 Interventions to minimize posttransplantation bone loss are summarized in Table 7. Implementation of these measures immediately after transplantation is essential, as most of the bone loss occurs in the first 6 months when the doses of steroids are highest. The role of DEXA in the diagnosis and of bisphosphonates in the prevention of posttransplantation bone disease requires further prospective study. There is evidence that bisphosphonates effectively prevent posttransplantation bone loss, 127 but trials reported to date have been underpowered to detect reductions in posttransplantation fracture rates. There is still some concern that these agents, by suppressing bone remodeling, could worsen the mechanical integrity of bone in conditions such as osteomalacia or adynamic bone.126 Furthermore, albeit at very high doses, bisphosphonates can be nephrotoxic.128 A reasonable approach is to obtain DEXA of 3 bone sites lumbar spine, forearm, and hip ; at the time of transplantation in patients with conventional risk factors for osteoporosis. In those considered to be at high risk for osteoporosis-related fracture based on clinical features and DEXA results, posttransplantation administration of bisphosphonates and the use of minimal-dose steroids or of nonsteroid protocols should be considered. Close collaboration with a bone endocrinologist in these situations is also advised. All patients should receive calcium and synthetic forms of vitamin D after kidney transplantation unless there are contraindications. Hyperparathyroidism Incomplete resolution of hyperparathyroidism is very common after re.
This is the second edition of the U-M Prescription Drug Plan Newsletter. This newsletter is being sent to all participants in the University of Michigan prescription drug plan. In this issue, we are pleased to provide you with information that includes approval of new drugs to our plan, new over-the-counter OTC ; medications, how to find the co-pay for any drug, and helpful tips for vacation or other travel medication needs. Each section includes a link to the U-M Benefits Office Web site where you can find additional details and the most current updates for each topic. Please email your comments or questions to benefits.office umich.
N July of 1989, allergists and pulmonary specialists pulmonologists ; at the Brigham and Women's Hospital began a collaboration that has endured and expanded over the ensuing 15 years. We defined the Mission of our Asthma Center at the outset, and have held to it ever since: .to provide optimal medical care for persons with asthma and related diseases; to develop new knowledge about asthma and its management through state-of-the-art medical research; to train medical students and graduate physicians in the specialized skills of asthma care; and to promote improved understanding about asthma and related diseases through educational programs and materials for our patients, for other health care providers, and for the community. We began as the "Longwood Medical Area Adult Asthma Center, " but in 1995, after creation of the Partners HealthCare System, we "morphed" into Partners Asthma Center and expanded our collaboration to include allergists and pulmonologists at other Partners-affiliated hospitals: Massachusetts General Hospital, Faulkner Hospital, Newton-Wellesley Hospital, and North Shore Medical Center. We are now more than 50 participating physicians and nurses -- with shared knowledge about asthma and philosophies of care -- providing services at multiple different practice sites throughout the greater Boston community and North Shore. Our asthma center is committed to medical research and to medical education for physicians and allied health care providers. Clinician-scientists at Partners Asthma Center.
Pitalised patients were included in the study. Demographic data, area of admission, underlying diseases, Wilson's severity index, APACHE II scoring, Charlson's comorbidity index, community or nosocomial acquisition of bacteraemia, and responsible microorganism were recorded on the previously prepared forms. Blood cultures were obtained from all patients at least two times. All patients were examined for ocular lesions with the same ophthalmologist in 4872 h after the first visit. Results: Thirty-one 20.7% ; patients were septic-bacteraemic, 43 28.7% ; were septic nonbacteraemic, 19 12.7% ; were severe inflammatory response syndrome SIRS; 16 10.7% ; were nonseptic nonbacteraemic infectious; and 23 15.3% ; were control. We found bacteraemia related ocular lesions BROLs ; in 22 14.7% ; patients. Winston scores were lower in the patients those have BROLs than others. According to the underlying diseases; there were more BROLs at the septic or bacteraemic patients with cancer 27.3% ; and central nervous system CNS ; diseases 31.8% ; than the others. The most detected agent at bacteraemia that has BROLs was Pseudomonas spp 27.3% ; , the second agent was Staphylococcus spp 22.7% ; . Conclusion: As a result; BROLs were more frequent at bacteraemic-septic patients 12.7% ; than the other groups. The most predisposing underlying diseases for BROLS were cancer and CNS diseases. Ocular examinations can give a clue for sepsis for this type of patients.
Feldene gel side effects
Feldenw, feldend, feldens, fldene, fedene, feldeen, felxene, felden4, fsldene, feldenee, felfene, efldene, teldene, fepdene, felcene, feld4ne, fledene, feldenr, feldfne, f3ldene, eldene, reldene, f4ldene, feldeme, fwldene, feldenne, frldene, celdene, feldne, feldsne.
Feldene and piroxicam, buy feldene online, feldene gel side effects, feldene drug interactions and feldene hotel blackpool. Feldene flash drug study, feldene drug classification, feldene qd and what is feldene gel or feldene hydrochloride.
Feldene drug interactions
Subconjunctival hemorrhage cure, gonadotropin effect, salivary amylase journal, metrogel interactions and nexium vs zantac. Stomach flu fever, schizophrenia support groups, strain definition and mometasone and formoterol or atonic epileptic seizure.
|
